Exelixis ((EXEL)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: The clinical study titled A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (KEYMAKER-U03): Substudy 03C aims to assess the safety and efficacy of experimental drug combinations in patients with clear cell renal cell carcinoma (ccRCC) who have experienced disease recurrence during or after anti-PD-(L)1 therapy. This study is significant as it explores new treatment options for a challenging patient population.
Intervention/Treatment: The study tests two experimental drug combinations: Zanzalintinib with Belzutifan. Both are administered as oral tablets and are intended to manage disease progression in ccRCC patients.
Study Design: This interventional study follows a non-randomized, parallel assignment model with a single-masked outcomes assessor. It includes two phases: a safety lead-in phase and an efficacy phase, focusing primarily on treatment.
Study Timeline: The study began on July 20, 2025, with the latest update submitted on August 18, 2025. These dates are crucial as they mark the progress and current status of the study, which is still recruiting participants.
Market Implications: The ongoing study could influence Exelixis’s stock performance positively if the results show promise, potentially boosting investor confidence. This development is particularly relevant in the competitive oncology market, where innovative treatments are highly valued.
The study is ongoing, with further details available on the ClinicalTrials portal.